Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 1, 2009, Pages 143-152

  Lacy, Brian E ^a   Chey, William D ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chloride; Chloride channels; Constipation; Functional bowel disorders; Gastrointestinal motility; Intestinal secretion; Irritable bowel syndrome; Lubiprostone

Indexed keywords

BISACODYL; CASCARA; CHLORIDE CHANNEL; DOCUSATE SODIUM; ISPAGULA; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL; MAGNESIUM CITRATE; OPIATE; OSMOTIC AGENT; PLACEBO; SODIUM DIHYDROGEN PHOSPHATE; CLC 2 CHLORIDE CHANNELS; CLC-2 CHLORIDE CHANNELS; DRUG DERIVATIVE; GASTROINTESTINAL AGENT; PROSTAGLANDIN E1;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CHRONIC DISEASE; CLINICAL TRIAL; COLONOSCOPY; CONSTIPATION; DIARRHEA; DIETARY INTAKE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EXERCISE; FECES ANALYSIS; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT; GENDER; HEADACHE; HOSPITAL COST; HUMAN; IRRITABLE COLON; LIFESTYLE; NAUSEA; NONHUMAN; QUALITY OF LIFE; REPRODUCTION; REVIEW; SEX DIFFERENCE; SODIUM TRANSPORT; TERATOGENICITY; TREATMENT RESPONSE; VOMITING; CHANNEL GATING; DRUG EFFECT; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; ION CHANNEL GATING; IRRITABLE BOWEL SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 65549109893     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802631319     Document Type: Review

References (45)

1. Higgins PDR, Johanson JF. Epidemiology of chronic constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-759
2. Lacy BE, Cole MS. Constipation in the older adult. Clin Geriatr 2004;12:44-54
3. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-1993
4. Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23:461-467
5. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-177
6. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927-934
7. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580
8. Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000;95:2816-2824
9. Luscombe FA. Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Qual Life Res 2000;9:161-176
10. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestives diseases in the United States. Gastroenterology 2002;122:1500-1511
11. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-3129
12. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491
13. Brandt LJ, Prather CM, Quigley EMM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100:S5-22
14. Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs 1998;21:156-161
15. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005;100:232-242
16. Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol 2006;2:736-749
17. Chen TY. Structure and function of ClC channels. Annu Rev Physiol 2005;67:809-839
18. Suzuki M, Morita T, Iwamoto T. Diversity of Cl channels. Cell Mol Life Sci 2006;63:12-24
19. Mindell JA, Maduke M. ClC chloride channels. Genome Biol 2001;2:3003.1-3003.6
20. Lipecka J, Bali M, Thomas A, et al. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol 2002;282:C805-16
21. AMITIZA® (lubiprostone) [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2006
22. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004;287:C1173-83
23. Bao HF, Liu L, Self J, et al. A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008;295:234-251
24. Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterol 2004;126:A298
25. Perentesis GP, Crawford DF, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Am J Gastroenterol 2005;100:S330
26. Cuppoletti J, Malinowska DH, Chakrabarti J, Ueno R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Med 2008;86:56-60
27. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-135
28. Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci 1994;14:2854-2860
29. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
30. Crawford DF, Perentesis GP, Engelke KJ, Ueno R. Effects of lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats. Am J Gastroenterol 2005;100:S331
31. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361
32. Johanson JF, Morton D, Geenan J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2007;103:170-177
33. Johanson JF, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am J Gastroenterol 2005;100:S324-5
34. Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primacy efficacy. Am J Gastroenterol 2005;100:S328-9
35. Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterol 2004;126:A100
36. Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterol 2006;130:A317
37. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs.female subjects. Gastroenterol 2006;130:A322
38. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696
39. Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterol 2007;132:2586-2587
40. Chey WD, Drossman DA, Scott C, et al. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008;134(Suppl 1):A215
41. Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil 2005;17:626
42. Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterol 2007;132:A191-2
43. Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterol 2007;132:A325
44. Ueno R, Hiroyoshi O, Engelke KJ. Effect of lubiprostone on morphine-induced constipation and analgesia. Gastroenterol 2006;130:A373-4
45. Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007;292:G647-56